Literature DB >> 3822132

Intracerebral hemorrhage and phenylpropanolamine use.

C S Kase, T E Foster, J E Reed, E L Spatz, G N Girgis.   

Abstract

Two patients developed intracerebral hemorrhage within hours from first-time ingestion of phenylpropanolamine-containing medications. One patient had marked hypertension, presented with three intracerebral hematomas, and developed a fourth hemorrhage 10 days later. Angiogram in one patient revealed "beading" of intracranial arteries, an abnormality also detected in a third patient who developed severe headache, vomiting, and acute hypertension following a single dose of phenylpropanolamine. These cases and others reported in the literature strongly suggest an association between phenylpropanolamine ingestion and hemorrhagic stroke. Direct questioning of use of this medication in cases of unexplained intracranial hemorrhage in previously healthy young individuals may reveal an unsuspected high frequency of this association.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3822132     DOI: 10.1212/wnl.37.3.399

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  The acute effect of phenylpropanolamine and brompheniramine on blood pressure in controlled hypertension: a randomized double-blind crossover trial.

Authors:  A S Petrulis; T F Imperiale; T Speroff
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 2.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 4.  Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Authors:  Y W Lam; A M Shepherd
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.